Prosensa has expanded its portfolio of potential treatments for Duchenne muscular dystrophy (DMD)

  • Prosensa has expanded its portfolio of potential treatments for Duchenne muscular dystrophy (DMD) based on skipping specific exons (sections) of the dystrophin gene; some of its exon-skipping program is being carried out in partnership with GlaxoSmithKline (GSK).
  • Compounds targeting exons 51 (drisapersen) and 44 (PRO044) are in clinical trials for DMD.
  • Compounds targeting exons 52 and 55 will be moved to clinical trials as soon as possible.
  • Compounds targeting exons 45 and 53 have received orphan drug designation from the European Commission and are expected to enter clinical development within the next six months.

Views: 532

Reply to This

Replies to This Discussion

Surely this means the results for 51 & 44 are very positive?

Race is on!

Lisa-

Almost never do I find anything of value on the Yahoo finance message boards.

But here is a nugget that may provide some insight from business POV on what is coming out of GSK. I DO NOT PERSONALLY VOUCH FOR ANY OF THESE STATEMENTS... just thought I would share what may be the first useful exchange of ideas I've seen on Yahoo in many months

http://finance.yahoo.com/mbview/threadview/?&bn=8725fb77-7f25-3...

I too hope that the big player GSK just gives up the legal struggle and somehow licenses/buys/merges technology from Sarepta. Would save huge on legal fees alone, and the boys are biggest winners.

Thanks for the link David. There's speculation on the message board that Sarepta's compound could be on the market by next summer if they receive accelerated approval. That seems wildly optimistic. Thoughts?

Reply to Discussion

RSS

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service